Touyz, R. M. and Harrison, D. G. (2023) Hope for resistant hypertension through BrigHTN and PRECISION. Nature Reviews Nephrology, 19(4), pp. 216-217. (doi: 10.1038/s41581-023-00676-2) (PMID:36658403)
Full text not currently available from Enlighten.
Abstract
An estimated 10–15% of individuals with hypertension are resistant to available antihypertensive therapies. Findings from two new clinical trials — BrigHTN and PRECISION — that assessed the blood pressure-lowering effects of the aldosterone synthase inhibitor baxdrostat and the dual endothelin receptor antagonist aprocitentan, respectively, suggest these approaches hold promise for patients with treatment-resistant hypertension.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Harrison, Professor David and Touyz, Professor Rhian |
| Authors: | Touyz, R. M., and Harrison, D. G. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | Nature Reviews Nephrology |
| Publisher: | Nature Research |
| ISSN: | 1759-5061 |
| ISSN (Online): | 1759-507X |
| Published Online: | 19 January 2023 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details